Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies

DUBLIN, July 1, 2013 /PRNewswire/ --

Research and Markets ( http://www.researchandmarkets.com/research/zsvknx/competitor) has announced the addition of the "Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

This report provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies in the market, in the pipeline as next generation products and as biosimilar versions as of December 2012. Purchase of the downloadable PDF report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Marketed antibodies are attractive for companies to create next generation variants and biosimilar copies because they represent clinically and commercially validated products. New technologies such as Fc engineering, polyclonal mixtures, antibody drug conjugates or bi-specific molecules as well as the expiration of patents stimulate the discovery and development of biosimilar and bio-superior/bio-better molecules.

The cumulated sales volume of therapeutic antibodies for which biosimilar antibodies are in the R&D pipeline was as high as US$ 54.7 billion in the year 2011 with double digit growth rates of many representative of them:

- Rituxan/MabThera
- Arzerra
- Erbitux
- Vectibix
- Herceptin
- Avastin
- Lucentis
- Enbrel
- Remicade
- Humira
- Cimzia
- Simponi
- Actemra/RoActemra
- ReoPro
- Campath
- Orencia
- Tysabri
- Xolair
- Synagis
- Prolia/Xgeva
- Soliris
- Stelara
- Zenapax



More than 140 biosimilar antibodies are in the pipeline with the first molecules approved in non-regulated markets. The regulation of the development of biosimilar antibodies in the European Union has facilitated the submission of an MAA of a first biosimilar antibody from a Korean company.

The report includes a compilation of currently active projects in research and development of biosimilar and bio-superior antibodies against commercially and clinically validated targets:

- CD20
- Her2
- VEGF
- TNF
- EGF-R
- CD52
- GPIIb/IIIa
- B7.1/B7.2 (CD80/CD86)
- IL-6R
- Alpha4/beta1/7 integrin
- IgE
- RSV
- RANKL
- Complement C5
- IL-12/IL-23
- CD25 (IL-2R)


Competitor projects are listed in a tabular format providing information on:

- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.

For more information visit  http://www.researchandmarkets.com/research/zsvknx/competitor

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals


SOURCE Research and Markets



More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.